Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial
Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima, Hiroshi Morimatsu, Hiroshi Ogura, Yoshitsugu Yamada, Tetsuji Nagano, Eiichiro Morishima, Naoyuki Matsuda
Topics & Concepts
MedicineOpen labelAntagonistSepsisAnesthesiaRandomized controlled trialPharmacologyInternal medicineReceptorSepsis Diagnosis and TreatmentCardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and Outcomes